BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37813015)

  • 1. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting
    Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
    Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
    Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].
    Ren C; Cao H; Zheng J; Sun W; Zhou J
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):291-302. PubMed ID: 37183644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab in the treatment of non-small cell lung cancer.
    Azzoli CG; Krug LM; Miller VA; Kris MG; Mass R
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):59-65. PubMed ID: 11894015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.
    Zinner RG; Kim J; Herbst RS
    Lung Cancer; 2002 Jul; 37(1):17-27. PubMed ID: 12057863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.